Healing Through Psychedelics: Ketamine, MDMA, and Psilocybin with Chris Caldwell

Healing Through Psychedelics: Ketamine, MDMA, and Psilocybin with Chris CaldwellIn this powerful opening episode of Conscious Physician: Medicine & Psychedelics, Dr. Lida Fatemi interviews Chris Caldwell and explores the emerging role of psychedelics in end-of-life and palliative care. The conversation centers on how substances such as ketamine, MDMA, and psilocybin are being thoughtfully integrated to address physical pain, psychological trauma, existential distress, and unresolved relational wounds in patients facing terminal illness.Through clinical insights and personal stories, this episode highlights the importance of education, community support, and individualized treatment approaches when working with psychedelics in sensitive medical contexts. Listeners are introduced to the evolving landscape of research, nonprofit education efforts, and policy shifts—particularly in states like Oregon—that are shaping the future of psychedelic-assisted care.This episode sets the foundation for the podcast by bridging medicine, consciousness, and compassionate care, while examining both the promise and the challenges of psychedelic therapies in modern healthcare.Key TakeawaysThe nonprofit End of Life Psychedelic (founded in 2023, founded by Chris Caldwell) focuses on education and community support for psychedelic use in end-of-life settingsPsychedelics may significantly reduce suffering at the end of life by addressing pain, trauma, and existential distressKetamine is currently used for pain management and trauma resolution in terminal patientsMDMA shows promise in helping patients process guilt, grief, and relationship challengesPsilocybin can facilitate profound spiritual experiences, acceptance, and meaning-makingIndividualized treatment approaches are essential in psychedelic-assisted therapyOngoing research continues to explore psychedelics’ role in palliative and hospice careMicrodosing may support cognitive function and emotional well-beingOregon’s evolving policies are creating pathways for non-medical psychedelic useLegislative changes are needed to expand access, particularly in home-based and end-of-life care settingspsychedelics, end-of-life care, ketamine, MDMA, psilocybin, palliative care, mental health, trauma, education, community support